We analyzed 3,872 common genetic variants across the ESR1 locus (encoding estrogen receptor a) in 118,816 subjects from three international consortia. We found evidence for at least five independent causal variants, each associated with different phenotype sets, including estrogen receptor (ER + or ER − ) and human ERBB2 (HER2 + or HER2 − ) tumor subtypes, mammographic density and tumor grade. The best candidate causal variants for ER − tumors lie in four separate enhancer elements, and their risk alleles reduce expression of ESR1, RMND1 and CCDC170, whereas the risk alleles of the strongest candidates for the remaining independent causal variant disrupt a silencer element and putatively increase ESR1 and RMND1 expression.
with breast cancer risk for CIMBA BRCA1 mutation carriers and risk of ER − tumors in BCAC. We anticipated that this analysis would increase statistical power to detect ER − risk signals, and, indeed, it did strengthen the evidence for association of SNPs representing signals 1-4 but not signal 5, which showed no association with breast cancer risk in BRCA1 mutation carriers ( Table 1) .
Tumor subtype and grade analyses
We next explored the associations of each signal with specific tumor subtype combinations and with tumor grade (Fig. 1f , Table 2 and  Supplementary Tables 3-5 ). The representative SNPs at two signals (3 and 5) were strongly associated with high-grade disease, after adjusting for ER status (P < 1 × 10 −3 ; Table 2 (bottom line) and Supplementary  Table 5 ). Among ER − tumors, three signals (1, 2 and 4) were associated with triple-negative (ER − PR − HER2 − ) and high-grade tumors, as well as the rarer ER − PR − HER2 + subtype, with similar odds ratios ( Table 2  and Supplementary Tables 3 and 5 ). However, signal 5 was more strongly associated with ER − PR − HER2 + disease (odds ratio (OR) = 1.24, 95% confidence interval (CI) = 1.12-1.37; P = 2.4 × 10 −5 ; Table 2 ) than with the triple-negative subtype (OR = 1.08, 95% CI = 1.01-1.15; P = 0.016; Table 2 , case-only P = 0.021; Supplementary Table 5) , consistent with the lack of association for breast cancer in BRCA1 mutation carriers, in whom tumors are predominantly triple negative 8 .
Haplotype analysis
We next explored the combined effects of the same five signalrepresentative genotyped SNPs (Supplementary Table 6 ). Haplotypespecific effects were consistent with additive effects of the individual signal-representative SNPs. In particular, haplotype 22221 (all minor alleles except for signal 5; frequency = 0.005) was associated with the largest increased risks of both ER + (OR = 1.38, 95% CI = 1.11-1.71; P = 3.3 × 10 −3 ) and ER − (OR = 2.34, 95% CI = 1.76-3.10; P = 3.5 × 10 −9 ) tumors; this group includes the triple-negative (ER − PR − HER2 − ) tumor subtype (detected via the meta-analysis of BCAC subjects with ER − tumors and CIMBA BRCA1 mutation carriers; P = 8 × 10 −10 ). Haplotype 22111 (frequency = 0.02) was associated with the highest risk of HER2 + tumors (OR = 1.5, 95% CI = 1.21-1.87; P = 3 × 10 −4 ) and with mammographic dense area (β coefficient = 0.45, 95% CI = 0.20 to 0.69; P = 3 × 10 −4 ).
Associations in Asian-ancestry studies
We examined the associations of the five signal-representative SNPs in the nine Asian-ancestry studies in BCAC (Supplementary Table 7 ). All five displayed allelic associations in the same direction as in Europeans, with overlapping confidence intervals, consistent with the hypothesis that the same candidate causal variants determine risk in both populations. 
A r t i c l e s
Determining the candidate SNPs within each signal To identify the potential causal variants to be taken forward for functional analysis, we determined the most significant SNP association within each signal and then calculated the likelihood ratio of every other SNP relative to that SNP. We assumed that SNPs with a likelihood of <1:100 (ref. 9) in comparison with the most significant SNP for each signal could be excluded from consideration as potentially causative variants. On the basis of the assumption that, within a given signal, the same variant(s) would be driving all observed phenotype associations, we derived the list of most likely causal SNPs for each signal. We used the results from one of two analyses to define the list of potentially causal SNPs for each signal: the meta-analysis of BCAC subjects with ER − disease and CIMBA BRCA1 mutation carriers for signals 1, 2 and 4, which were most strongly associated in this analysis, and overall breast cancer risk in BCAC for signals 3 and 5. These lists of unexcluded variants are presented in Table 3 and are highlighted in Supplementary Table 1 .
In signal 1, the most strongly associated variant was rs2046210 (the original Asian GWAS hit 1, 10 Fig. 2a and Supplementary Figs. 1 and 2) .
(ii) ESR1 expression in breast tumors and adjacent normal breast tissue from the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) study was compared relative to signalrepresentative SNP allele ( Fig. 2b and Supplementary Table 8 ). In patients with ER − tumors, risk allele carriers had lower median ESR1 expression in normal, tumor-adjacent tissue than homozygotes for the protective allele at signals 1, 4 and 5, although none of the differences were statistically significant. By contrast, in patients with ER + tumors, risk allele carriers had higher median ESR1 expression in normal, tumor-adjacent tissue than homozygotes for the protective allele at signals 1, 3 and 5. (iii) Allele-specific expression (ASE) analysis, using RNA sequencing (RNA-seq) data from breast tumor samples and SNP array genotype data from The Cancer Genome Atlas (TCGA) 11 , showed allelic imbalances in ESR1 expression among heterozygotes for proxy SNPs in signals 1-3 ( Fig. 2c and Supplementary Table 9) . For each signal-representative SNP (the best associated genotyped SNP), odds ratios for the minor/major allele and conditional odds ratios (OR and cOR) together with 95% confidence intervals (CIs), hazard ratios (HR and cHR), β coefficients (β and cβ) and P values (P cond ) are from models including the other four signal-representative SNPs. Representative conditional odds ratios and confidence intervals could not be generated from the meta-analysis.
NA indicates that the SNP was not included in conditional analysis because its individual effect was not significant at Fig. 4 ). Chromatin conformation capture (3C) experiments demonstrated that elements within signals 1 and 2 physically interacted with the promoters of ESR1, RMND1-ARMT1 and CCDC170 in MCF-7 and T-47D cells ( Fig. 3b and Supplementary Fig. 5a,b) . Furthermore, we detected interactions between signals 3-5 and ESR1 and/or RMND1-ARMT1 promoters (Fig. 3c,d and Supplementary Fig. 5c,d ). The majority of these interactions were restricted to MCF-7 and T-47D cells (ER + breast cancer cell lines), but the RMND1-ARMT1 interactions were also detected in either Bre-80 or MCF10A cells (ER − 'normal' breast cell lines; Fig. 3b-d and Supplementary Fig. 5b-d) . The 3C-identified interactions for each signal are summarized in Supplementary Table 12 .
Prioritizing candidate SNPs for functional assays
We applied a combination of in silico and in vitro analyses to prioritize candidate causal SNPs for functional follow-up, using previous observations that common cancer susceptibility alleles are enriched in cis-regulatory elements [14] [15] [16] . First, Table 3 showed that 19 of the 26 top candidates overlapped DNase I-sensitive sites and were associated with enhancer-enriched histone marks such as dimethylation of histone H3 at lysine 4 (H3K4me2) and H3K27ac in MCF-7 and HMEC breast cells, indicative of putative regulatory elements (PREs) (Supplementary Fig. 6 ). In electromobility Similar imbalances in CCDC170 expression were detected among heterozygotes for signal 2 SNP rs9397437 and in RMND1 expression with signal 3 SNP rs851983 (Supplementary Table 9 ). Such allelic imbalances indicate that risk alleles at these signals are associated with expression differences in local genes, but they do not indicate the directions of association. (iv) Expression quantitative trait locus (eQTL) analysis using the Gene-Tissue Expression (GTEx) database identified a significant association for SNPs in signal 3 with CCDC170 expression in normal breast tissues (Supplementary Table 10) . We also performed cis-eQTL analyses on the 12 flanking genes in 135 normal breast tissue samples from the METABRIC study; however, no additional associations were detected (Supplementary Table 11 ).
Bioinformatic and chromatin analyses
Analysis of cis enhancer-gene interactions using PreSTIGE 12 showed evidence of multiple regulatory elements coinciding with signals 1-3 in ER + MCF-7 breast cancer cells ( Fig. 3a and Supplementary Fig. 3) . A 'super-enhancer' , associated with high levels of acetylation of histone H3 at lysine 27 (H3K27ac), was also identified in MCF-7 cells and encompasses the top risk-associated SNPs in these three signals ( Fig. 3a and Supplementary Fig. 3 ) 13 . This super-enhancer was most readily detectable in MCF-7 cells and was not observed in other breast cancer cell lines, normal mammary epithelial cells or other Red lines and whiskers correspond to means ± 1 s.d. For rs7740686 (signal 1) and rs9397437 (signal 2), Levene's test (equality of variances) was used to calculate the P values; for rs851985 (signal 3), a two-tailed t test (equality of means) was used to calculate the P value.
npg
A r t i c l e s shift assays (EMSAs), 11 of these 19 SNPs altered the binding affinity of transcription factors in vitro (Supplementary Fig. 7 ). Of these, seven fell within promoter-specific long-range interactions identified by 3C ( Fig. 3 and Supplementary Fig. 5 ). The 7 SNPs prioritized for further detailed analyses included 2 of 10 remaining candidates in signal 1 (rs7763637 and rs6557160), 1 of 3 candidates in signal 2 (rs17081533), 2 of 4 candidates in signal 3 (rs851982 and rs851983), 1 of 3 candidates in signal 4 (rs1361024) and 1 of 6 candidates in signal 5 (rs910416) (Supplementary Table 12 ).
Luciferase reporter assays
The regulatory capabilities of the PREs overlapping each signal and the effects of the seven prioritized candidate SNPs were examined in luciferase reporter assays in the ER + MCF-7 and BT-474 and the ER − Bre-80 breast cell lines. PRE constructs containing the reference alleles of the prioritized SNPs for signals 1, 2, 4 and 5 significantly increased associated target gene promoter activity when cloned in either direction, indicating that they act as orientation-independent transcriptional enhancers. In contrast, a PRE containing the reference alleles of the signal 3 candidates ablated target gene promoter activity, but only when cloned in the forward direction, suggesting that this region acts as an orientation-dependent silencer ( Fig. 4 and Supplementary Figs. 8-10) . Notably, inclusion of the minor (risk) alleles of individual candidate SNPs in signals 1, 2 and 5 (rs6557160, rs17081533 and rs910416) significantly reduced ESR1 and RMND1 promoter activity but had no effect on the ARMT1 or CCDC170 promoters. However, inclusion of the signal 1 haplotype significantly decreased ESR1, RMND1 and CCDC170 promoter activity (Fig. 4 and Supplementary Figs. 8 and 9) . Inclusion of the individual minor (risk) allele of signal 4 SNP rs1361024 or signal 3 SNP rs851983 in the respective constructs had no additional effects. In contrast, inclusion of the signal 3 minor (risk) allele of rs851982 or the haplotype construct increased ESR1 promoter activity in ER + MCF-7 and BT-474 cells and RMND1 promoter activity in all three cell lines (Fig. 4, Supplementary Figs. 8 and 9 , and Supplementary Table 12 ).
Transcription factor binding analyses
We used both bioinformatic analyses and functional studies to examine DNA-protein interactions for the seven prioritized SNPs.
In silico prediction tools including intragenomic replicates (IGR) 17 , HaploReg 18 and Alibaba2 (ref. 19 ) predicted that all seven SNPs alter transcription factor binding ( Supplementary Fig. 11 and Supplementary Table 13 ).
Competition with known transcription factor binding sites suggested the identity of bound proteins for four of the prioritized SNPs, including GATA3 binding to the minor (risk) allele of signal 3 SNP rs851982 and CTCF binding to the minor allele of a second signal 3 candidate, rs851983, as well as the common (protective) allele of signal 4 candidate rs1361024 and MYC binding to the common allele of signal 5 candidate rs910416 (Supplementary Fig. 12 and Supplementary  Table 12 ). Additional well-established breast cell transcription factors, such as ER itself and FOXA1, were also assessed but did not display competitive binding to any prioritized SNP sites (Supplementary Fig. 13 ). Chromatin immunoprecipitation (ChIP) confirmed enrichment of GATA3 binding to DNA overlapping signal 3 candidate rs851982, but no difference between the alleles, and confirmed CTCF binding to the region overlapping signal 4 candidate rs1361024 in BT-474 cells ( Fig. 5a and Supplementary Fig. 14) . CTCF also bound to the region encompassing signal 3 candidate rs851983 (Fig. 5a, Supplementary Fig. 14 and Supplementary Table 12) . CTCF mediates long-range chromatin looping; therefore, to assess the potential impact of signal 4 candidate rs1361024 and signal 3 candidate rs851983 on chromatin interactions, we performed allelespecific 3C in heterozygous cell lines. Sequence profiles indicated that the protective G allele of signal 4 candidate rs1361024 increases looping between this enhancer and the ESR1 and RMND1 promoters ( Fig. 5b and Supplementary Fig. 15a ). We found no evidence for allele-specific looping between the silencer overlapping signal 3 and local gene promoters (Supplementary Fig. 15b ).
DISCUSSION
The fine-scale mapping, bioinformatic and functional analyses presented here provide evidence for the existence of at least five different genetic variants, each with a direct effect on breast cancer risk in Europeans, findings also supported by the limited available data in Asian populations. 22 . We also found evidence that the candidate causal variants at signals 3 and 5 predispose to aggressive, high-grade breast cancer, independently of ER status. Figure 4 Risk alleles reduce ESR1 and RMND1 promoter activity. Luciferase reporter assays were performed following transient transfection of ER + MCF-7 breast cancer cells. PREs containing the major SNP alleles were cloned downstream of target gene promoter-driven luciferase constructs (prom) for the creation of reference (Ref-PRE) constructs. Minor SNP alleles were engineered into the constructs and are designated by the rsID of the corresponding SNP. "Haplotype" denotes a construct that contains the minor alleles of both candidate SNPs within signal 1 or 3. Error bars, 95% confidence intervals from three independent experiments. P values were determined by two-way ANOVA followed by Dunnett's multiplecomparisons test: **P < 0.01, ***P < 0.001. 
A r t i c l e s
Mammographic density adjusted for age and body mass index (BMI), which describes the variation in epithelial and stromal tissue on a mammogram, is one of the strongest known risk factors for breast cancer 23 and has been shown to have a shared genetic basis with breast cancer, mediated through a large number of common variants 24 . Associations between ESR1 SNPs and mammographic density have previously been reported [25] [26] [27] , but, in this detailed analysis, only signal 2 was significantly associated with mammographic dense area (P = 1.7 × 10 −5 ), although signal 1 also showed some evidence of an effect in the conditional analysis (P = 0.017). Although adjusting the breast cancer analysis of signal 2 for mammographic dense area produced some attenuation of the associated effect, the lead SNP remained significantly associated with breast cancer risk (unconditional OR = 1.30, 95% CI = 1.13-1.49; P = 0.00024; OR conditional on dense area = 1.24, 95% CI = 1.08-1.43; P = 0.0025), suggesting either that the mechanism by which the signal 2 candidate causal variant affects breast cancer risk is not mediated through mammographic density or, alternatively, that dense area, as measured here, is unable to capture the association with breast composition that is most relevant to risk. This phenomenon, whereby the association with risk appears to be partially independent of mammographic density, has also been observed for the 10q21.2 breast cancer locus 4 .
SNPs in the ESR1 region have previously been reported to be associated with bone mineral density 28, 29 . These include SNPs within signal 1 (rs6930633, r 2 = 0.73 with rs3757322) and signal 3 (rs2982575, r 2 = 0.57 with rs851984), although the SNP with the most significant reported association with bone density measures, rs4870044, was not associated with breast cancer risk (P > 1 × 10 −4 ) in our analysis nor correlated with any signal-representative SNPs (r 2 <0.06). Similarly, SNP rs6933669, recently reported as associated with age at menarche 30 , is uncorrelated with these five signals (r 2 <0.02) and was not associated with breast cancer (P = 0.1). Thus, although there is a known relationship between age at menarche and breast cancer risk, these phenotypes do not appear to share candidate causal variants in this region.
Our findings help address the question of the role of ERα in establishing breast cancer. Notably, the candidate causal SNPs identified here all increase risks of both ER + and ER − tumor subtypes by varying degrees. ERα is a ligand-activated transcription factor that mediates the effect of estrogen through altering gene expression, and the links between estrogen, ERα and ER + breast cancer are well documented, with adjuvant endocrine therapy considered standard treatment for ER + , early-stage breast cancer. Other studies have also reported 6q25 associations with ER − subtypes 1,2,5 , but the mechanisms by which ER − tumors develop are still debated. There is speculation that ER − tumors may arise from ER + precursors by potentially reversible mechanisms, and our findings may lend support to this hypothesis. However, several recent studies have indicated that most tumors in BRCA1 mutation carriers arise from ER − luminal progenitor cells; thus, estrogen may be working indirectly through paracrine regulation in the mammary epithelium, possibly stimulating the Notch or epidermal growth factor receptor (EGFR) signaling pathways of adjacent ER + cells 31, 32 . Our analyses unexpectedly suggested that, whereas signals 1-4 increased risks of all ER − tumor subtypes, the signal 5 candidate causal variant increased risks of ER − HER2 + breast cancer subtypes but not of triple-negative tumor development or of tumors in BRCA1 mutation carriers ( Table 1) . This further complicates present understanding and underlines the need for further studies to address this issue.
Collectively, our evidence supports a hypothesis that ESR1 is the major target gene of the enhancer and silencer elements in which we have identified candidate causal variants. In addition to ESR1, we provide evidence that the regions overlapping signals 1-4 cooperatively regulate RMND1, raising the possibility that candidate causal SNPs act by altering both ESR1 and RMND1 expression. RMND1 (required for meiotic nuclear division 1; C6orf96) has not been well characterized but is reported to localize to mitochondria and be involved in mitochondrial translation 33 . We additionally identified enhancer activity and chromatin interactions with two other genes, ARMT1 and CCDC170, but the actions of the candidate causal SNPs on these genes remain unclear. ARMT1 encodes Armt1, a protein carboxyl methyltransferase that targets PCNA and differentially regulates cancer cell survival in response to DNA damage 34 . Nothing is known about the function of CCDC170 (coiled-coil domain-containing protein 170), but recurrent ESR1-CCDC170 rearrangements have been characterized in an aggressive subset of ER + breast cancers 35 . A recent study also showed that higher CCDC170 expression correlated with ER negativity, highly proliferative features and worse clinical outcomes 36 . There are some data to suggest that these genes may cooperatively contribute to the increased proliferative capacity of ER + tumors 20 , and it is tempting to speculate that these may be additional target genes for the candidate causal variants at a subset of the five signals identified here and perhaps responsible for their differential phenotype associations. A greater understanding of these genes may also provide novel targets for breast cancer prevention or therapies. 
METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes. The relevant SNP genotype data underpinning these analyses can be accessed by applying to the BCAC and CIMBA consortia (see URLs). 
